FDCNSEFDC Limited· PharmaceuticalsMediumPositive
Announced Mon, 18 May · 10:44 IST

FDC Limited has informed the Exchange about General Updates

Regulatory Product ApprovalBusiness Updates View source PDF

FDC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.6%1-day move
₹364.10
prior close
₹358.25
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.8+0.9+1.2+1.0-0.6-1.1-0.3+1.9+1.1+15.9+8.2+5.8+14.4
Up moveDown movePending
AI summary

FDC Limited has received ANDA (Abbreviated New Drug Application) approval from the US FDA for Cefixime for Oral Suspension USP in two dosage strengths - 100 mg/5 mL and 200 mg/5 mL. The approval was disclosed under SEBI Listing Regulations, specifically Regulation 30. This generic antibiotic drug can now be manufactured and marketed in the United States. No specific revenue projections or order values were disclosed in the filing.

Likely market impact

The US FDA approval opens the US generic pharmaceutical market to FDC for this antibiotic product, potentially boosting export revenue in USD. The actual commercial impact will depend on market penetration and pricing.